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Abstract To investigate the role of phosphorylation of a pre- 
cursor form of interleukin-lc~ (pre-IL-la), we obtained cells pro- 
ducing either phosphorylated or unphosphorylated pre-IL-la. 
Although calcium-dependent proteolytic processing of unphos- 
phorylated pre-IL-la could be observed in cell lysates, prot- 
eolytic processing was not induced by treatment with calcium 
ionophore in intact cells producing the unphosphorylated pre-IL- 
la .  Further, unphosphorylated pre-IL-la showed no calcium- 
dependent binding to acidic phospholipids at concentrations below 
5 × 10 -6 M. These results suggested that phosphorylated pre-IL- 
la  became susceptible to proteolytic processing by association 
with the cell membrane in a calcium-dependent manner. 
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1. Introduction 
Interleukin-1 (IL-1) has pleiotropic biological activities im- 
plicated in a variety of physiological processes [1]. There are 
two distinct types of IL-1, termed IL- I~ and IL-lfl, both of 
which have been cloned [2-5]. Both types of IL-1 are primarily 
translated as 33-kDa molecules (pre-IL- 1).Then, pre-IL- 1 ~ and 
pre-IL- lfl are post-translationally processed into 17-kDa mole- 
cules (mature IL-1) mediated by calpain (EC 3.4.22.17) [6,7] 
and IL-lf l  converting enzyme [8,9], respectively, followed by 
the extracellular release of mature IL-1. 
Intracellular pre- IL- l~ is phosphorylated at serine residue(s) 
in the precursor egion at levels at least 10-fold higher than 
intracellular pre-IL-lf l  [10,11]. We also described previously 
that processing of pre- IL- l~ into mature IL- I~ was induced by 
increases in intracellular calcium concentration [6], and that in 
vitro phosphorylated human pre-IL-lc~ bound to acidic 
phospholipids in a calcium-dependent manner [12]. These re- 
sults suggested the possibility thatthe selective phosphorylation 
of pre-IL-lc~ is related to its calcium-dependent proteolytic 
processing. In this study, we tested this possibility by construct- 
ing a mutant pre-IL-lc~ lacking phosphorylation sites. Our re- 
sults indicated that the phosphorylation of pre-IL- l~ might 
facilitate calcium-dependent association with the cell mere- 
brane where pre-IL-1 ~ becomes usceptible to proteolytic proc- 
essing. 
2. Materials and methods 
2.1. Antibodies 
Rabbit anti-IL-l~ was prepared by immunizing rabbits with human 
rIL-l~ [10], and was used for immunoprecipitation. The antigen speci- 
ficity was confirmed by immunoprecipitation, Western blotting, and 
neutralization experiments [10], and pre-IL-l~ as well as mature IL-I~ 
was equally recognized by this antibody [13]. 
2.2. Plasmid construction 
The I L-I~ expression plasmid was constructed as follows. The PstI- 
HincII fragment (0.9 kb) of pilL4 [10], which contains the coding 
region of pre-IL-l~, was inserted into pUG131 [14] treated with PstI 
and EcoRV. This plasmid (pUHL(PH)) was digested with BglII and 
SmaI, following the end-filling of protruding ends, and ligated with a 
XbaI linker. The linker-ligated XbaI fragment (0.9 kb) was replaced 
with the XbaI stuffer fragment of pEF-BOS [15], which contains the 
human elongation factor 1~ promoter. 
For site-directed mutagenesis, the PstI-HincII fragment of pilL4 
was inserted into M13tgl31 treated with PstI and EcoRV. Single- 
stranded phage DNA was used as a template for mutagenesis by the 
method escribed by Kunkel et al. [16]. Mutated pre-IL-10~ cDNA was 
also inserted into pEF-BOS as described above. The primers used for 
the mutagenesis are shown in Fig. 1. 
2.3. Cell culture and DNA transfection 
NIH/3T3 cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). The IL-I~ 
expression plasmid DNA (20 ¢tg) and pSV2neo plasmid DNA (0.5/lg) 
carrying the neomycin resistance gene were cotransfected into NIH/3T3 
cells by the calcium phosphate precipitation method [17]. Colonies 
resistant to the antibiotic G418 (active concentration, 250/zg/ml) were 
isolated and IL-lc~ activity in cell lysates was measured by incorpora- 
tion of [3H]thymidine into the IL-1- and IL-2-dependent cell line 
D 10G4N. 
2.4. Metabolic labelling of cells with F: P]orthophosphate 
NIH/3T3 cells producing pre-IL-1 ~ in 35-mm dishes were rinsed with 
phosphate-free Hanks' balanced salt solution (HBSS), placed at 37°C 
for 30 min, and then labelled by incubation at 37°C for an additional 
2 h with 0.1 mCi of[3ZP]orthophosphate (2 mCi/ml; 1 Ci = 37 GBq, ICN 
Biomedicals Inc., Costa Mesa, USA) in 1 ml of phosphate-free HBSS. 
Labelled cell lysates prepared as described previously [6] were im- 
munoprecipitated with rabbit anti-human IL-I~ antibodies [10] and 
analyzed by sodium dodecyl sulfate-polyacrylamide gel lectrophoresis 
(SDS-PAGE) [18]. Gels were dried and exposed to Kodak XAR film 
at -80°C. 
*Corresponding author. Fax: (81) (474) 72 7696. 
Abbreviations." IL-1, interleukin-1; DMEM, Dulbecco's modified 
Eagle's medium; FCS, fetal calf serum; HBSS, Hanks' balanced salt 
solution; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel elec- 
trophoresis; MEM, minimum essential medium; EGTA, ethylene glycol 
bis-]~3-aminoethyl ether N,N,N',N'-tetraacetic acid; BSA, bovine serum 
albumin; LPS, lipopolysaccharide; CHAPS, 3-[(3-cholamidopropyl)- 
dimethylammonio]- 1 -propanesulfonate. 
2.5. Metabolic labelling of cells with FSS]methionine 
NIH/3T3 cells producing pre-IL-1 ~ in 35-mm dishes were labelled by 
incubation at 37°C for 2 h with 0.1 mCi of L-[35S]methionine (Tran35S - 
label, specific activity 1037 Ci/mmol; ICN Biomedicals Inc.) in 1 ml of 
methionine-free minimum essential medium (MEM) supplemented 
with 2% FCS. Labelling medium was replaced with l ml of DMEM 
supplemented with 2% FCS (chase) in the presence or absence of 
calcium ionophore (A23187, Sigma) nd incubated for 30 min. The 
resultant culture supernatants and cell lysates prepared as described 
previously [6] were immunoprecipitated with rabbit anti-human IL-I~ 
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antibodies [10] and analyzed by SDS-PAGE [18]. Gels were treated with 
Enlightning (Dupont/NEN Research Products), dried, an  exposed to
Kodak XAR films at -80°C. The radioactivities of IL-I~ bands in the 
gel were quantitated using a Bio-imaging analyzer (Fuji Photo Film 
Co., Ltd.). 
2.6. Preparation f 35S-labelled pre-IL-lo~ 
Cells were labelled with L-[35S]methionine and the resultant cell ly- 
sates were prepared as described above. Labelled pr -IL-l~ was puri- 
fied by immuno-affinity column chromatography [19] from the cell 
lysates. 
2. 7. Binding of pre-IL-l~ to phophatidic acid 
Phosphatidic a id vesicles were prepared as described previously [12] 
except rehydration with 10 mM Tris-buffered saline (pH 8.0) containing 
2 mM ethylene glycol bis-fl3-aminoethyl et erN,N,N',N'-tetraacetic 
acid (EGTA). Phosphatidic a id vesicles at a final concentration of 0.4 
mg/ml were incubated with 35S-labelled pre-IL-lc~ in the absence or 
presence of 1, 2, 3 or 4 mM CaC12 for 30 min at 22°C, followed by 
harvesting on a Millipore filter (GVWP025) presoaked in the rehydra- 
tion buffer supplemented with 1 mg/ml bovine serum albumin (BSA). 
Each filter was washed twice with rehydration buffer for the CaC12-free 
samples or 10 mM Tris-buffered saline (pH 8.0) for the CaC12-contain- 
ing samples, then dried, an  the radioactivity was counted. 
3. Results 
3.1. Isolation of cells producing the unphosphorylated pre-IL-l~ 
We and others reported previously that most pre-IL-l~ is 
phosphorylated in lipopolysaccharide (LPS)-activated human 
monocytes [10,11]. Although the precise in vivo phosphoryla- 
tion sites of pre-IL- la were unknown, our experimental data 
using a synthetic peptide (residues 84 to 112) showed that all 
or any of 4 serine residues close to dibasic/tetrabasic amino acid 
sequence were phosphorylated [10] as shown in Fig. 1. 
To investigate the role of phosphorylation f pre-IL-la, we 
constructed the S mutant in which all of 4 serine residues likely 
to be phosphorylated were converted into glycine residues by 
site-directed mutagenesis (Fig. 1). When NIH/3T3 cell clones 
expressing the S mutant were labelled with [32p]ortho- 
phosphate, pre-IL- la was phosphorylated in all the clones 
tested to the same extent as in cells expressing the wild-type 
IL - la  (data not shown). By limited proteolysis with trypsin, 
phosphorylated amino acid(s) in the S mutant were localized 
in the same trypsin fragment, in which phosphorylated serine 
residues were present [13] (data not shown). Since it was sug- 
gested that the site of phosphorylation was not present in ma- 
P ~d E s~ P 
p.L, L 
S4 107 
wild type ArgArgLeuSerLeuSerGlnSerIleThrAspAspAspLeuGluAlaIl®AlaAmnAspSerGluGluGlu 
. . . . . . . .  gArgLe~e~l~ ........ pAspAspL ............... ~ ........ 
. . . . . . . .  gArgLe~e~l~I  l~pAspAspL  .......... 1 . . . .  ~ ........ 
3' - TCCGGTTCCGTA~CTACTACTGGAC-  5 ' 
Fig. 1. Amino acid and nucleotide sequences in the phosphorylated 
region of pre-IL-la. The primers used for mutagenesis are shown below 
the amino acid sequences ofS and ST mutants. Nucleotides andamino 
acids replaced in the mutants are boxed. The coding region fpre-IL-1 
in pilL4 is shaded. 
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Fig. 2. Phosphorylation a d synthesis of pre-IL-I c~. Cells were labelled 
with [nP]orthophosphate (A) or L-[35S]methionine (B). The resultant 
cell lysates prepared from the NIH/3T3 cells expressing wild-type 
IL-lc~ (lane 1) and ST mutant (lane 2), or untransfected NIH/3T3 cells 
(lane 3) were immunoprecipitated by anti-IL-lc~ antibodies and ana- 
lyzed by SDS-PAGE. The arrows indicate the migration posotions for 
pre-IL-lcc 
ture IL-I~ [10] and that trace amounts of phosphothreonine 
were detected in purified [nP]orthophosphate-labelled pr -IL- 
lcc [10], we considered that one threonine residue adjacent to 
these 4 serine residues might be phosphorylated. Therefore, this 
threonine residue was further converted into a glycine residue 
(ST mutant, see Fig. 1). 
In the NIH/3T3 cell clone expressing the wild-type IL-lc~, 
phosphorylated forms of pre-IL- 1 ~ were detected (Fig. 2A, lane 
1). In contrast, in the cell clone expressing the ST mutant, 
phosphorylation of pre-IL-l~ was hardly detected (Fig. 2A, 
lane 2), although 35S-labelled pre-IL-l~ was present (Fig. 2B, 
lane 2). 
3.2. Processing and release of unphosphorylated lL-lo~ 
Although pre-IL-kz produced by LPS-activated human 
monocytes i inefficiently processed and released, we and oth- 
ers described previously that the processing of pre-IL-lc~ into 
mature IL-lc~ was enhanced by increases in intracellular cal- 
cium concentration [6,20]. We also described previously that 
processed mature IL-I~ was selectively released from the cells 
and that the amount of pre-IL-l~ released paralleled lactate 
dehydrogenase activity, suggesting that the release of pre-IL- 1 
might result from cell damage [21]. When cells producing the 
wild-type IL- 1 c~ were treated with A23187, proteolytic process- 
ing of pre-IL-lc~ was induced and accompanied by the release 
of mature IL-I~ (Fig. 3A). In contrast, in cells producing the 
unphosphorylated pre-IL-l~, processing of pre-IL-l~ was 
hardly detected by treatment with A23187, although trace 
amounts of processed IL-I~ were observed intracellularly by 
treatment with 10 ktM of A23187 (Fig. 3B). As a result, the 
release of mature IL-lc~ was hardly detected in cells producing 
the unphosphorylated IL-I~. However, when cell lysates pre- 
pared from cells producing the unphosphorylated pre-IL-lc~ 
were incubated in the presence of CaC12, processing into mature 
IL-I~ was observed (Fig. 4, lane 4). The percentage of process- 
ing in unphosphorylated pre-IL-1 cc was nearly the same as that 
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in phosphorylated pre-IL- la (Fig. 4). Thus, these results dem- 
onstrated that the phosphorylation f pre-IL- la did affect its 
susceptibility to calcium-dependent proteolytic processing in 
intact cells but not in cell lysates. 
3.3. Calcium-dependent binding of pre-IL-l~ to phosphatidic acid 
According to our preliminary results, in vitro phosphorylated 
pre-IL- la was bound to membrane in the presence of CaC12 
[12]. We therefore xamined whether the phosphorylation of
pre-IL- la was related to the association with phospholipids. 
Phosphorylated and unphosphorylated pre-IL- 1~ as binding 
substrates were affinity-purified from HTB9 5637 cells [6] and 
ST mutant-expressing cells. As shown in Fig. 5, phosphorylated 
pre-IL- la bound to phosphatidic acid in a calcium-dependent 
manner. In contrast, unphosphorylated pre- IL - la  showed rel- 
atively low calcium-dependency compared to the phosphorylated 
form. At physiological concentrations of intracellular calcium, 
that is below 5 × 10 -6 M, unphosphorylated pre-IL- la showed 
no calcium-dependent binding, suggesting that the phosphoryl- 
ation of pre-IL- la affects the calcium-dependent association 
with cell membrane. 
A 
. . . . . . . . . . . . . .  
1 2 3 4 5 6 7 8 
97 
- -66  
- -45  
- -  31 
'2 '2 
- -1.1 
k I)~L 
B 
Fig. 3. Processing and release of IL-1 a by treatment with A23187. Cells 
expressing wild-type IL-la (A) and ST mutant IL-I~ (B) were labeled 
with L-[35S]methionine and chased in the absence (lanes 1 and 5) or 
presence of 2,uM (lanes 2 and 6), 5/~M (lanes 3 and 7), or 10tiM (lanes 
4 and 8) A23187. The resultant cell lysates (lanes 1 to 4) and super- 
natants (lanes 5 to 8) were imunoprecipitated and analyzed by 
SDS-PAGE. The arrows indicate the migration positions for pre-IL-la 
(33 kDa) or mature IL-I~ (17 kDa). 
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Fig. 4. Calcium-dependent processing of pre-IL-la in the cell lysates. 
Cells expressing wild-type IL-la (lanes 1 and 2) and ST mutant IL-la 
(lanes 3 and 4) were labelled with L-[35S]methionine as described in 
section 2 and lysed with 1 ml of 9 mM 3-[(3-cholamidopropyl)dimethyl- 
ammonio]-l-propanesulfonate (CHAPS) in 20 mM Tris-HC1 (pH 8.0) 
with 5 mM EGTA (lanes 1 and 3) or 1 mM CaC12 (lanes 2 and 4), After 
incubation at 37°C for 30 min, each cell lysate was immunoprecipitated 
and analyzed by SDS-PAGE. The ratio of mature IL-1 a in the presence 
of CaC12 was indicated below the autoradiogram. The amounts of pre- 
and mature IL-la were corrected based on the differences in number 
of methionine residues between h  two forms. The arrows indicate the 
migration positions for pre-IL-l~ (33 kDa) or mature IL-la (17 kDa). 
4. Discussion 
In this study, we explored the role of phosphorylation of
pre-IL- la by the alteration of phosphorylated residues into 
unphosphorylated residues. Although unphosphorylated as
well as wild-type pre-IL- la served as substrates for calcium- 
dependent processing protease in cell lysates, unphosphorylated 
pre-IL- la was hardly processed in intact cells by increases in 
intracellular calcium concentration and showed no calcium- 
dependent binding to phosphatidic acid at physiological intra- 
cellular calcium concentrations. We and others demonstrated 
that calcium-dependent proteolytic processing of pre-IL- la in 
cell lysates was selectively mediated by calpain [6,7]. Calpain is 
believed to be converted to an active form by binding to 
phospholipids in a calcium-dependent manner [22], although 
the activated form of calpain has never been isolated from 
tissues. Therefore our results uggested that calcium-dependent 
association of phosphorylated pre-IL- la with the cell mem- 
brane might be necessary for proteolytic processing by calpain. 
Adachi et al. [23] also reported that phosphorylated forms of 
calpastatin, an endogeneous calpain inhibitor, were distributed 
in the membrane fraction compared to unphosphorylated 
forms, although they did not examine the effects of calcium on 
its change in distribution. 
Since phosphoamino acid analysis of human pre-IL- la re- 
vealed that phosphoserine was predominant [10], all the 4 serine 
residues likely to be phosphorylated were mutated (S mutant). 
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Fig. 5. Calcium-dependent binding of phosphorylated and unphos- 
phorylated pre-IL-l~ to phosphatidic acid. Affinity-purified 
35S-labelled phosphorylated (1216 dpm) and unphosphorylated pre-IL- 
let (416 dpm) were incubated with phosphatidic acid vesicles in the 
absence or presence ofCaC12. Relative binding activity was expressed 
as the ratio of binding activity to that in the presence of EGTA. 
However, cells expressing the S mutant showed phosphoryla- 
tion similarly to those expressing the wild-type pre-IL-l~. Al- 
though we did not determine the phosphorylated amino acid(s) 
in the S mutant, threonine, trace amounts of which were phos- 
phorylated in the wild-type pre-IL-l~ [10], might be phos- 
phorylated compensating for the mutation of serine residues in 
the S mutant. As a result of the further alteration of the threon- 
ine residue into glycine residue (ST mutant), we obtained cells 
expressing the unphosphorylated pre-IL-l~. 
When calpain is converted to an activated form after cal- 
cium-dependent translocation to the cell membrane, the cal- 
cium-binding domain, the E-F  hand structure in calpain, is 
involved in the calcium-dependent translocation to the cell 
membrane [24]. It was also reported that cytosolic phospholip- 
ase A2 was translocated via a calcium-dependent phospholipid- 
binding motif [25]. Although it was clear that calcium was 
required for the activation in calpain in the processing of pre- 
IL-lc~, we did not know how pre-IL-l~ translocated in a cal- 
cium-dependent manner, since pre-IL-lct has no known cal- 
cium-binding domains. 
Even unphosphorylated pre-IL-l~ bound to phosphatidic 
acid in a calcium-dependent manner, although the increase of 
binding induced by calcium was significantly lower than in 
phosphorylated pre-IL-l~. This increase of binding of un- 
phosphorylated pre-IL-l~ to phosphatidic acid might be due 
to a conformational change caused by the alteration of amino 
acids. That trace amounts of processed form of unphosphoryl- 
ated pre-IL-l~ were detected intracellularly in the presence of 
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10 /tM A23187 might have been caused by this increase in
binding. 
In conclusion, our findings supported the model that the 
translocation of phosphorylated pre-IL- la to the cell mem- 
brane was necessary for its proteolytic processing induced by 
calcium ionophore. Although we do not have any direct evi- 
dence supporting that the same model is applicable to LPS- 
activated macrophages, it is pertinent to introduce our recent 
observation that LPS could increase intracellular calcium con- 
centration in murine macrophage cell line, J774.1. Although it 
seemed that the phosphorylation was necessary for the binding 
of pre-IL- la to acidic phospholipids, we do not know whether 
acidic phospholipids inside the cell membrane are the main 
target of the binding of pre-IL-1 c~. We are currently investigat- 
ing this point directly. 
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